Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Trojan, J; Mineur, L; Tomasek, J; Rouleau, E; Fabian, P; de Maglio, G; Garcia-Alfonso, P; Aprile, G; Taylor, A; Kafatos, G; Downey, G; Terwey, JH; van Krieken, JH.

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

PLoS One. 2015; 10(10): Nº de citas: 10 [doi:10.1371/journal.pone.0140717]

Noriega, V; Martinez-Laperche, C; Buces, E; Pion, M; Sanchez-Hernandez, N; Martin-Antonio, B; Guillem, V; Bosch-Vizcaya, A; Bento, L; Gonzalez-Rivera, M; Balsalobre, P; Kwon, M; Serrano, D; Gayoso, J; de la Camara, R; Brunet, S; Rojas-Contreras, R; Nieto, JB; Martinez, C; Gonzalez, M; Espigado, I; Vallejo, JC; Sampol, A; Jimenez-Velasco, A; Urbano-Ispizua, A; Solano, C; Gallardo, D; Diez-Martin, JL; Buno, I.

The Genotype of the Donor for the (GT)(n) Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation

PLoS One. 2015; 10(10): Nº de citas: 10 [doi:10.1371/journal.pone.0140454]

Escobar, Y; Cajaraville, G; Virizuela, JA; Alvarez, R; Munoz, A; Olariaga, O; Tames, MJ; Muros, B; Lecumberri, MJ; Feliu, J; Martinez, P; Adansa, JC; Martinez, MJ; Lopez, R; Blasco, A; Gascon, P; Calvo, V; Luna, P; Montalar, J; Del Barrio, P; Tornamira, MV.

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

SUPPORTIVE CARE IN CANCER. 2015; 23(9): 2833-2840 Nº de citas: 68 [doi:10.1007/s00520-015-2809-3]

Casla, S; Lopez-Tarruella, S; Jerez, Y; Marquez-Rodas, I; Galvao, DA; Newton, RU; Cubedo, R; Calvo, I; Sampedro, J; Barakat, R; Martin, M.

Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial

BREAST CANCER RESEARCH AND TREATMENT. 2015; 153(2): 371-382 Nº de citas: 86 [doi:10.1007/s10549-015-3541-x]

Pereira, A; Mendizabal, E; de Leon, J; Perez-Medina, T; Magrina, JF; Magtibay, PM; Rodriguez-Tapia, A; Lizarraga, S; Ortiz-Quintana, L.

Peritoneal carcinomatosis: A malignant disease with an embryological origin?

SURGICAL ONCOLOGY-OXFORD. 2015; 24(3): 305-311 Nº de citas: 6 [doi:10.1016/j.suronc.2015.06.002]

Giuliano, M; Hu, HZ; Wang, YC; Fu, XY; Nardone, A; Herrera, S; Mao, SF; Contreras, A; Gutierrez, C; Wang, T; Hilsenbeck, SG; De Angelis, C; Wang, NJ; Heiser, LM; Gray, JW; Lopez-Tarruella, S; Pavlick, AC; Trivedi, MV; Chamness, GC; Chang, JC; Osborne, CK; Rimawi, MF; Schiff, R.

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

CLINICAL CANCER RESEARCH. 2015; 21(17): 3995-4003 Nº de citas: 101 [doi:10.1158/1078-0432.CCR-14-2728]

Carrato, A; Garcia, P; Lopez, R; Macarulla, T; Rivera, F; Sastre, J; Gostkorzewicz, J; Benedit, P; Perez-Alcantara, F.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2015; 15(4): 579-589 Nº de citas: 12 [doi:10.1586/14737167.2015.1047349]

Cajal, TRY; Chirivella, I; Miranda, J; Teule, A; Izquierdo, A; Balmana, J; Sanchez-Heras, AB; Llort, G; Fisas, D; Lope, V; Hernandez-Agudo, E; Juan-Fita, MJ; Tena, I; Robles, L; Guillen-Ponce, C; Perez-Segura, P; Luque-Molina, MS; Hernando-Polo, S; Salinas, M; Brunet, J; Salas-Trejo, MD; Barnadas, A; Pollan, M.

Mammographic density and breast cancer in women from high risk families

BREAST CANCER RESEARCH. 2015; 17: Nº de citas: 20 [doi:10.1186/s13058-015-0604-1]

Capdevila, J; Sevilla, I; Alonso, V; Aparicio, LA; Fonseca, PJ; Grande, E; Reina, JJ; Manzano, JL; Lajara, JDA; Barriuso, J; Castellano, D; Medina, J; Lopez, C; Segura, A; Carrera, S; Crespo, G; Fuster, J; Munarriz, J; Alfonso, PG.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

BMC CANCER. 2015; 15: Nº de citas: 24 [doi:10.1186/s12885-015-1512-6]

Larkin, J; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Cowey, CL; Lao, CD; Schadendorf, D; Dummer, R; Smylie, M; Rutkowski, P; Ferrucci, PF; Hill, A; Wagstaff, J; Carlino, MS; Haanen, JB; Maio, M; Marquez-Rodas, I; McArthur, GA; Ascierto, PA; Long, GV; Callahan, MK; Postow, MA; Grossmann, K; Sznol, M; Dreno, B; Bastholt, L; Yang, A; Rollin, LM; Horak, C; Hodi, FS; Wolchok, JD.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2015; 373(1): 23-34 Nº de citas: 7145 [doi:10.1056/NEJMoa1504030]

Martin, M.

nab-Paclitaxel dose and schedule in breast cancer

BREAST CANCER RESEARCH. 2015; 17: Nº de citas: 21 [doi:10.1186/s13058-015-0587-y]

Tejera-Alhambra, M; Casrouge, A; de Andres, C; Seyfferth, A; Ramos-Medina, R; Alonso, B; Vega, J; Fernandez-Paredes, L; Albert, ML; Sanchez-Ramon, S.

Plasma Biomarkers Discriminate Clinical Forms of Multiple Sclerosis

PLoS One. 2015; 10(6): Nº de citas: 47 [doi:10.1371/journal.pone.0128952]

Martin, M; Gonzalez-Rivera, M; Morales, S; de la Haba-Rodriguez, J; Gonzalez-Cortijo, L; Manso, L; Albanell, J; Gonzalez-Martin, A; Gonzalez, S; Arcusa, A; de la Cruz-Merino, L; Rojo, F; Vidal, M; Galvan, P; Aguirre, E; Morales, C; Ferree, S; Pompilio, K; Casas, M; Caballero, R; Goicoechea, U; Carrasco, E; Michalopoulos, S; Hornberger, J; Prat, A.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

CURRENT MEDICAL RESEARCH AND OPINION. 2015; 31(6): 1129-1137 Nº de citas: 28 [doi:10.1185/03007995.2015.1037730]

Castello, A; Martin, M; Ruiz, A; Casas, AM; Baena-Canada, JM; Lope, V; Antolin, S; Sanchez, P; Ramos, M; Anton, A; Munoz, M; Bermejo, B; De Juan-Ferre, A; Jara, C; Chacon, JI; Jimeno, MA; Rosado, P; Diaz, E; Guillem, V; Lluch, A; Carrasco, E; Perez-Gomez, B; Vioque, J; Pollan, M.

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

PLoS One. 2015; 10(5): Nº de citas: 64 [doi:10.1371/journal.pone.0126096]

Gelmon, KA; Boyle, FM; Kaufman, B; Huntsman, DG; Manikhas, A; Di Leo, A; Martin, M; Schwartzberg, LS; Lemieux, J; Aparicio, S; Shepherd, LE; Dent, S; Ellard, SL; Tonkin, K; Pritchard, KI; Whelan, TJ; Nomikos, D; Nusch, A; Coleman, RE; Mukai, H; Tjulandin, S; Khasanov, R; Rizel, S; Connor, AP; Santillana, SL; Chapman, JAW; Parulekar, WR.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(14): 1574 Nº de citas: 149 [doi:10.1200/JCO.2014.56.9590]

Tabernero, J; Yoshino, T; Cohn, AL; Obermannova, R; Bodoky, G; Garcia-Carbonero, R; Ciuleanu, TE; Portnoy, DC; Van Cutsem, E; Grothey, A; Prausova, J; Garcia-Alfonso, P; Yamazaki, K; Clingan, PR; Lonardi, S; Kim, TW; Simms, L; Chang, SC; Nasroulah, F.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

LANCET ONCOLOGY. 2015; 16(5): 499-508 Nº de citas: 773 [doi:10.1016/S1470-2045(15)70127-0]

Cheang, MCU; Martin, M; Nielsen, TO; Prat, A; Voduc, D; Rodriguez-Lescure, A; Ruiz, A; Chia, S; Shepherd, L; Ruiz-Borrego, M; Calvo, L; Alba, E; Carrasco, E; Caballero, R; Tu, DS; Pritchard, KI; Levine, MN; Bramwell, VH; Parker, J; Bernard, PS; Ellis, MJ; Perou, CM; Di Leo, A; Carey, LA.

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

ONCOLOGIST. 2015; 20(5): 474-482 Nº de citas: 172 [doi:10.1634/theoncologist.2014-0372]

Garcia-Alfonso, P; Chaves, M; Munoz, A; Salud, A; Garcia-Gonzalez, M; Gravalos, C; Massuti, B; Gonzalez-Flores, E; Queralt, B; Lopez-Ladron, A; Losa, F; Gomez, MJ; Oltra, A; Aranda, E.

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

BMC CANCER. 2015; 15: Nº de citas: 8 [doi:10.1186/s12885-015-1293-y]